{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"0.0"},{"groupId":"OG001","spread":"0.31","value":"-0.0"},{"groupId":"OG002","spread":"0.28","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"420"},{"groupId":"OG002","value":"381"}],"units":"Participants"}],"title":"Month 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.33","value":"0.1"},{"groupId":"OG001","spread":"0.32","value":"0.1"},{"groupId":"OG002","spread":"0.32","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"283"},{"groupId":"OG002","value":"366"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.32","value":"0.1"},{"groupId":"OG001","spread":"0.31","value":"0.1"},{"groupId":"OG002","spread":"0.34","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"351"},{"groupId":"OG002","value":"323"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.33","value":"0.1"},{"groupId":"OG001","spread":"0.31","value":"0.1"},{"groupId":"OG002","spread":"0.35","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"278"},{"groupId":"OG002","value":"231"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.36","value":"0.1"},{"groupId":"OG001","spread":"0.32","value":"0.1"},{"groupId":"OG002","spread":"0.35","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"230"},{"groupId":"OG002","value":"170"}],"units":"Participants"}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.40","value":"0.0"},{"groupId":"OG001","spread":"0.35","value":"0.0"},{"groupId":"OG002","spread":"0.39","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"231"},{"groupId":"OG002","value":"240"}],"units":"Participants"}],"title":"Discontinuation Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"490"},{"groupId":"OG001","value":"492"},{"groupId":"OG002","value":"490"}],"units":"Participants"}],"description":"EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.","dispersionType":"Standard Deviation","groups":[{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.","id":"OG000","title":"Lenalidomide and Low-Dose Dexamethasone (Rd)"},{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.","id":"OG001","title":"Lenalidomide and Dexamethasone Rd18"},{"description":"Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.","id":"OG002","title":"Melphalan + Prednisone + Thalidomide (MPT)"}],"paramType":"MEAN","populationDescription":"ITT population with available data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit","title":"Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}